CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m ...

AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, expectations were $1.07. Pascal Soriot ...

AstraZeneca PLC beat Q4 and full-year 2024 earnings estimates, with significant revenue and EPS growth, and forecasts further growth in 2025 despite China-related setbacks. The company faces ...

Second, thanks to the progress of our collaboration with AstraZeneca. Up to year-end 2024, $47 million have been paid to Cellectis under the joint research and collaboration agreement of which $25 ...

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total ... Read More on AZN: AstraZeneca NewsMORE Related Stocks ...

Reports Q4 revenue $1.99M vs $33.22M last year. “2024 has been an important year for Cellectis (CLLS): we are now developing three programs in ...

Compugen Ltd (CGEN) showcases promising developments in oncology treatments while navigating a decrease in annual revenue and ...

AstraZeneca PLC (NASDAQ:AZN) is facing ongoing investigations in China regarding suspected unpaid importation taxes, which could result in significant fines. The company experienced a 3% decline in Q4 ...

Cellectis demonstrated robust performance in Q4 2024, significantly outperforming market expectations. The company’s strategic initiatives, including its partnership with AstraZeneca ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.